In 653/716 (91.2%) patients information on the receptor status was available including 260/653 (39.8%) patients with HR+ BC, 230/653 (35.2%) with HER2+ BC and 163/653 (25.0%) with TN-BC. This evidence concerns the gene ERBB2 and breast cancer.